BioAtla Files 8-K for Shareholder Vote and Other Events

TL;DR

BioAtla filed an 8-K on 12/30/25 for a shareholder vote and other events. Details to follow.

AI Summary

BioAtla, Inc. filed an 8-K on December 30, 2025, to report on the submission of matters to a vote of security holders and other events. The filing does not contain specific details about the nature of the vote or the other events.

Why It Matters

This filing indicates that BioAtla, Inc. is engaging in corporate actions requiring shareholder approval or is disclosing significant events. Investors should monitor for further details on these matters.

Risk Assessment

Risk Level: low — The filing is procedural and does not contain information that immediately impacts the company's financial or operational standing.

Key Players & Entities

• BioAtla, Inc. (company) — Registrant
• December 30, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share BCAB Nasdaq Cap

Filing Documents

• bcab-20251230.htm (8-K) — 60KB
• 0001193125-25-337078.txt ( ) — 163KB
• bcab-20251230.xsd (EX-101.SCH) — 24KB
• bcab-20251230_htm.xml (XML) — 4KB

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. On December 30, 2025, BioAtla, Inc. (the "Company") held its special meeting of stockholders (the "Special Meeting"). The Special Meeting was held to consider and vote on the following proposals: (1) the potential issuance of 20% or more of the aggregate number of Company's common stock, par value $0.0001 per share ("Common Stock"), issued and outstanding as of November 20, 2025 pursuant to the Pre-Paid Advance Agreements, dated November 20, 2025 (the "Exchange Cap"), by and between the Company and each of YA II PN, Ltd., a Cayman Islands exempt limited company ("Yorkville"), Anson Investments Master Fund LP and Anson East Master Fund LP, and the Standby Equity Purchase Agreement, dated November 20, 2025, by and between the Company and Yorkville, pursuant to Nasdaq Listing Rule 5635(d) ("Proposal No. 1"); (2) an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, to, at the discretion of the Company's Board of Directors (the "Board"), effect a reverse stock split with respect to the Common Stock at any time prior to June 30, 2026, at a ratio of 1-for-5 to 1-for-20 (the "Range"), with the ratio within such Range to be determined at the discretion of the Board without further approval or authorization of the Company's stockholders ("Proposal No. 2"); and (3) the adjournment or adjournments of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are not sufficient votes in favor of Proposal No. 1 or Proposal No. 2 ("Proposal No. 3"). Present at the Special Meeting, in person or by proxy, were holders of 39,098,928 shares of Common Stock as of November 25, 2025 (the "Record Date"), representing at least a majority of the voting power of the shares of Common Stock issued and outstanding and entitled to vote at the Special Meeting as of the Record Date, which constituted a quorum for the transaction of busin

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioAtla, Inc. Date: December 30, 2025 By: /s/ Richard A. Waldron Richard A. Waldron Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR